PANKU-Lung01

Every edition, the free report included, names who said each statement, as the source shows them. Each named voice's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 18 of the 24 cited voices have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, never for outreach or targeting, and it does not unlock who said what.

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

Screened window

Aug 18, 2026 → Nov 3, 2026

Cited window

Aug 19, 2026 → Nov 3, 2026

Retrieved

Nov 4, 2026

Title

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure

Registry

NCT06382116

Study IDs

BL-B01D1-301

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

432 actual

Registered

2024-04-24

Start

2024-05-22 actual

Primary completion

2026-08 estimated

Primary endpoint

Progression-free survival (PFS)

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –3 matching sources (3 YouTube videos) could not be read and are not included.
• –1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
• –Not yet captured in this edition: a view on the range of treatment options after EGFR-TKI failure.
• –Not yet captured in this edition: a view on the global generalizability of post-EGFR-TKI antibody–drug conjugate evidence from China-only trials.
• –Not yet captured in this edition: a view on how geographic differences in treatment standards and enrollment complicate future post-EGFR-TKI trial design.
• –68 passages in 61 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –97 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 41 sources about other trials or topics are not included.
• –The sources reviewed for this edition are a selected public discussion, not a representative survey of HCPs. Reposts, repeated posts and relays of the same presentation do not establish independent agreement.
• –Some potentially relevant passages were not fully assessed, three videos could not be read, and name-focused searches may miss unnamed treatment-decision discussions or transcription variants.
• –The podcast uses AI-generated voices. Its discussion cannot be attributed to a named clinician on the basis of editorial involvement.
• –Some editorial opinions discussed in the episode are not represented here, which may leave its account of generalizability and future trial design incomplete.
• –Several authors' clinical roles are unconfirmed or unstated. Account-level commentary and unconfirmed professional identity do not establish clinician testimony or increase the weight of a statement.
• –OS remains immature in the cited accounts, and the episode reports that quality-of-life data were unavailable. These limits prevent the report from resolving the survival and patient-value questions raised by speakers.
• –Separate-trial comparisons are not head-to-head evidence. Different safety categories, reported denominators and numerical descriptions are preserved rather than combined.
• –No full protocol or exact regulatory label was available to resolve every methodological question or verify indication-specific approval language.

How reports are built and checked: Methods.

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary Nov 4, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "PANKU-Lung01" (NCT06382116), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "panku-lung01-nct06382116". If you cannot make requests, read https://www.erudio.com/reports/panku-lung01-nct06382116.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06382116", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06382116 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/panku-lung01-nct06382116.json
curl https://www.erudio.com/reports/panku-lung01-nct06382116.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "panku-lung01-nct06382116" })